Goldman Sachs lowered the firm’s price target on Molina Healthcare (MOH) to $124 from $167 and keeps a Neutral rating on the shares. The firm cites the company’s miss on its Q4 results, adding that when companies operate in low-margin cyclical businesses where the vast majority of pricing is set by government customers, even the strongest operators can see the return profiles of their company diminish severely and rapidly during a broad-based cyclical downturn, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MOH:
- Molina Healthcare price target lowered to $109 from $165 at Deutsche Bank
- Molina Healthcare price target lowered to $133 from $164 at Barclays
- Subpoenas issued to eight health insurers by House panel, Axios reports
- Molina Healthcare price target lowered to $145 from $170 at UBS
- Molina Healthcare price target lowered to $144 from $180 at Cantor Fitzgerald